Both in Pharmaceuticals
Lite Strategy vs Impact BioMedical
Over the past year LITS returned −38.8% and IBO returned −64.4%; their daily moves had a correlation of 0.11.
LITS −38.8% IBO −64.4%Growth of $1, one year, split-adjusted
| Metric | LITS | IBO |
|---|---|---|
| Price | $1.15 | $2.68 |
| Market cap | $35.0M | $22.9M |
| Today | −3.77% | −15.15% |
| 1 month | +10.6% | −62.8% |
| 6 months | −2.5% | −67.1% |
| Year to date | −12.9% | −57.9% |
| 1 year | −46.0% | −64.8% |
| Revenue growth (YoY) | — | −57.1% |
| Gross margin | — | −533.3% |
| Net margin | — | −23300.0% |
| P/E (TTM) | — | 29.0× |
| Price / sales | — | 654.2× |
| Net cash | $5.7M | $10.0K |
| Dividend yield | — | — |
| Volatility (60d) | 76.9% | 733.9% |
| Short % of float | 0.6% | 0.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).